Feist E, Fleischmann RM, Fatenejad S, et al. Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment. Annals of the Rheumatic Diseases 2024;83:1454-1464.
The correct Figure 2, Figure 3 including descriptions provided on y-axis are below:


